Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy

Sarepta Therapeutics (SRPT) shares plummeted over 47% following a second patient death related to its ELEVIDYS gene therapy, prompting trial suspensions and raising safety concerns. While the company's FY25 guidance was slashed, an analyst views the sell-off as overdone, citing strong year-over-year revenue growth of 180% for ELEVIDYS and 70% for overall product revenue, along with no new safety signals in over 800 treated patients, suggesting a favorable risk-reward profile for long-term investors.

Analysis

Sarepta Therapeutics (SRPT) experienced a precipitous stock decline, with shares plummeting over 47% to levels not seen since 2016. This dramatic downturn was triggered by the news of a second patient death associated with its ELEVIDYS gene therapy, which subsequently led to trial suspensions and heightened safety concerns, compelling the company to slash its FY25 guidance. Despite these significant setbacks and the resultant bearish sentiment, an analyst's perspective suggests the stock is now "deeply oversold." This contrarian view is partially supported by strong underlying financial metrics: ELEVIDYS revenue, while experiencing a sequential dip, still posted a substantial 180% year-over-year increase, and overall product revenue grew by 70% year-over-year. The analyst also highlights that no new safety signals have emerged from over 800 patients treated with ELEVIDYS, suggesting that with expectations now reset, the risk-reward profile at current valuation levels could be favorable for long-term investors, with potential upside anticipated in the second half of FY25.

Key Decisions for Investors

• Investors should carefully evaluate the significant stock depreciation and heightened safety concerns against the analyst's assessment of an oversold condition and the reported strong year-over-year revenue growth for ELEVIDYS (180%) and overall products (70%).
• Continuous monitoring of ELEVIDYS safety data, ongoing trial developments, and regulatory feedback is crucial, as these factors will heavily influence the company's trajectory and investor sentiment following the patient deaths.
• For those with a higher risk tolerance and a long-term investment horizon, the current suppressed valuation, coupled with the analyst's view of reset expectations and no new safety signals in a large patient cohort, may present a strategic entry point, contingent on further due diligence regarding the safety profile of ELEVIDYS.